Cheson on Oncology

 
 
  • FDA Sends Valentine to CLL Patients   The FDA approval of ibrutinib is a red-letter day for patients with relapsed chronic lymphocytic leukemia, because of the drug’s quick action and effectiveness, says Dr. Bruce Cheson.
  • Idelalisib Combo Rings Bells in Relapsed CLL   Patients with relapsed chronic lymphocytic leukemia, who were less able to undergo chemotherapy, had improved OS with a combination of idelalisib and rituximab, in a study reported by Dr Bruce Cheson.
  • Is Obinutuzumab the Drug to Watch in CLL? Drs. Cheson and Czuczman highlight data on obinutuzumab, ibrutinib, idelalisib, and emerging agents that are reshaping the leukemia and lymphoma landscape.
  • Novel Agents: Making the Benefit Last in CLL Drs. Susan O'Brien and Bruce Cheson discuss the exciting array of oral, well-tolerated, quick-acting therapies for CLL that provide durable if only partial remission.
  • Idelalisib Raises Eyebrows in Lymphoma   No blockbuster studies in lymphoma from ASH 2013, but real progress was made toward chemo-free regimens, as discussed by Drs. Gilles Salles and Bruce Cheson.
  • CLL Combos: And the Winner Is… The question of which is better -- FRC or BR -- is settled, sort of, at ASH 2013, in a study discussed by Drs. Bruce Cheson and Clemens Wendtner.
  • ASH 2013: Big Year for CLL, Lymphoma   Highlighting major studies and a plethora of new drugs, Dr. Bruce Cheson predicts that ASH 2013 will be a big year for non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.
  • Happy Felloween!   Who were those trick-or-treaters, dressed as missionaries, who came to Dr. Bruce Cheson's door on Halloween? Could they have been fellowship applicants?
  • 'Would You Sell Your Soul for $10?'   Dr. Bruce Cheson forecasts that the Sunshine Act, requiring physicians to disclose most payment and gifts from industry over $10, will bring showers of misinterpretation and could hinder research.
  • Lenalidomide Trial KO'd: A Blow to CLL Patients?   Dr. Bruce Cheson discusses the clinical ramifications of the decision to halt the ORIGIN trial, which compared lenalidomide vs chlorambucil in previously untreated elderly patients with CLL.
  • Hummus: Put That in Your Pipe and Smoke It   Dr. Bruce Cheson sees the popularity of hummus in the United States as having a positive effect on cancer prevention, as tobacco growers turn over a new leaf -- and plant chick peas.
  • Abandoning PETs in Lymphoma   Drs. Bruce Cheson and Gilles Salles discuss lymphoma highlights from ASCO 2013 on new targeted agents, potential combinations, and indications that surveillance requires few scans.
  • Bankruptcy or Cure? A Cancer Patient's Dilemma   The unsustainable cost of cancer drugs puts a possible cure out of the financial reach of many patients. Dr. Bruce Cheson calls for a concerted effort to cap escalating costs.
  • Blood's Up -- and So Are the Outcomes   Dr. Bruce Cheson highlights noteworthy studies in lymphoma, chronic lymphocytic leukemia, and multiple myeloma being presented at ASCO 2013.
  • Cure Cancer? Let's Rock and Roll!   Dr. Bruce Cheson discusses the new and much-touted strategy to cure cancer via a ‘band’ of all-stars.
  • Lugano: Destination Lymphoma   Dr. Bruce Cheson previews important studies to be presented at the International Conference on Malignant Lymphoma, the preeminent forum on lymphoma, to be held in Lugano, Switzerland, in June 2013.
  • Is R-Benda a New Standard in Lymphoma?   Dr. Bruce Cheson discusses the long-awaited StiL study. Do the results establish a new standard of therapy in lymphoma? Or do issues with the trial design leave the question unresolved?
  • BTK Inhibitors Open Door to Lymphoma Cure   Dr. Bruce Cheson reports on a plethora of data presented at ASH 2012 that heralds what he considers a new era in lymphoma management, one in which a cure may be in sight.
  • BRIGHT Not So Clear on Lymphoma Choice   The BRIGHT study presented at ASH 2012 showed R-bendamustine to be noninferior to R-CHOP, but what role each regimen plays in lymphoma management is still unclear, says Dr. Bruce Cheson.
  • ASH 2012: More Fuel for the Fire   Dr. Bruce Cheson highlights studies that should prove controversial and practice-changing, as well as new drugs that expand treatment options.